A previous expression profiling of VAT (visceral adipose tissue) revealed that the TSLP (thymic stromal lymphopoietin) gene was less expressed in severely obese men with (n = 7) compared with without (n = 7) the MetS (metabolic syndrome). We hypothesized that TSLP SNPs (single nucleotide polymorphisms) are associated with TSLP gene expression in VAT and with MetS phenotypes. Following validation of lower TSLP expression (P = 0.003) in VAT of severely obese men and women with (n = 70) compared with without (n = 60) the MetS, a detailed genetic investigation was performed at the TSLP locus by sequencing its promoter, exons and intronexon splicing boundaries using DNA of 25 severely obese subjects. Five tagging SNPs were genotyped in the 130 subjects from the expression analysis to test whether these SNPs contributed to TSLP expression variability (ANOVAs) and then genotyped in two independent samples of severely obese men (total, n = 389) and women (total, n = 894). In a sex-stratified multistage experimental design, ANOVAs were performed to test whether tagging SNPs were associated with MetS components treated as continuous variables. We observed that the non-coding SNP rs2289277 was associated with TSLP mRNA abundance (P = 0.04), as well as with SBP [systolic BP (blood pressure)] (P = 0.004) and DBP (diastolic BP) (P = 0.0003) in men when adjusting for age, waist circumference, smoking and medication treating hypertension. These novel observations suggest that TSLP expression in VAT may partly explain the inter-individual variability for metabolic impairments in the presence of obesity and that specific SNPs (rs2289277 and/or correlating SNPs) may influence TSLP gene expression as well as BP in obese men.
A B S T R A C T
A previous expression profiling of VAT (visceral adipose tissue) revealed that the TSLP (thymic stromal lymphopoietin) gene was less expressed in severely obese men with (n = 7) compared with without (n = 7) the MetS (metabolic syndrome). We hypothesized that TSLP SNPs (single nucleotide polymorphisms) are associated with TSLP gene expression in VAT and with MetS phenotypes. Following validation of lower TSLP expression (P = 0.003) in VAT of severely obese men and women with (n = 70) compared with without (n = 60) the MetS, a detailed genetic investigation was performed at the TSLP locus by sequencing its promoter, exons and intronexon splicing boundaries using DNA of 25 severely obese subjects. Five tagging SNPs were genotyped in the 130 subjects from the expression analysis to test whether these SNPs contributed to TSLP expression variability (ANOVAs) and then genotyped in two independent samples of severely obese men (total, n = 389) and women (total, n = 894). In a sex-stratified multistage experimental design, ANOVAs were performed to test whether tagging SNPs were associated with MetS components treated as continuous variables. We observed that the non-coding SNP rs2289277 was associated with TSLP mRNA abundance (P = 0.04), as well as with SBP [systolic BP (blood pressure)] (P = 0.004) and DBP (diastolic BP) (P = 0.0003) in men when adjusting for age, waist circumference, smoking and medication treating hypertension. These novel observations suggest that TSLP expression in VAT may partly explain the inter-individual variability for metabolic impairments in the presence of obesity and that specific SNPs (rs2289277 and/or correlating SNPs) may influence TSLP gene expression as well as BP in obese men.
INTRODUCTION
The clustering of metabolic and inflammatory alterations commonly observed among obese patients is often referred to as the MetS (metabolic syndrome) and considerably increases CVD (cardiovascular disease) risk [1, 2] . However, a significant proportion of obese individuals remain metabolically healthy while others are at increased risk for metabolic impairment and CVD [3, 4] . Among the factors contributing to such inter-individual variability, genetic variants [5, 6] and impairment of normal adipose tissue function [3] are suspected.
A previous gene expression profiling study of VAT (visceral adipose tissue) in non-diabetic severely obese men with and without MetS revealed a panel of genes differentially expressed between the two groups [7] . Of those, 25 transcripts were part of the immune and inflammatory response pathways, including that coding for the TSLP (thymic stromal lymphopoietin) cytokine. The TSLP gene was 1.70-fold less expressed (P < 0.001) in VAT of severely obese men with MetS than in those without (L. Bouchard, A. Tchernof, Y. Deshaies, S. Marceau, O. Lescelleur, S. Biron and M.-C Vohl, unpublished work). Its encoded cytokine appears to be an important mediator of immune cell homoeostasis and allergic inflammation [8, 9] . Since immune cells infiltrating VAT at the onset of obesity are involved in inflammation and obesity-related metabolic complications [10, 11] , TSLP may play a role in MetS development.
TSLP is a member of the haemopoietic cytokine family closely related to IL (interleukin)-7. Its gene is located on the 5q22.1 locus and spans approximately 7.8 kb. Alternative splicing of the TSLP gene results in two transcript variants of 2629 and 2411 bp. Only the longer transcript (GenBank ® accession number NM_033035.4) encodes the functional protein of 159 amino acids (RefSeq ID NP_149024; Consensus Coding Sequence ID CCDS4101.1), whereas there is uncertainty about the protein-coding capacity of the shorter transcript (RefSeq ID NR_033425.1). TSLP mRNA is predominantly expressed by epithelial cells in the thymus, lung, intestine, skin and tonsils, as well as in mast cells and certain type of stromal cells [9, 12] . It exerts its biological activities primarily in myeloid cells, such as monocytes, dentritic cells and T-cells by binding to its receptor [13] . TSLP can induce the release of chemokines from monocytes and dentritic cells favouring Th2 polarized Tcell formation [12, 13] , which appears to be a critical step in the pathogenesis of Th2-mediated allergic inflammation [12] . TSLP plays an important role in allergic diseases such as asthma and atopic dermatitis and may have a protective role in Crohn's disease [9] .
No study has reported previously an association between the TSLP gene and obesity-related metabolic complications. We have thus undertaken a validation of the differential omental TSLP expression between subjects with and without the MetS, as well as a comprehensive initial genetic investigation at the TSLP locus to verify whether SNPs (single nucleotide polymorphisms) within this gene contribute to explain TSLP gene expression and the inter-individual variability in MetS-associated phenotypes observed among severely obese individuals.
MATERIALS AND METHODS

Recruitment of severely obese subjects
From June 2000 to June 2009, 1297 severely obese Caucasian men and women undergoing a biliopancreatic diversion with sleeve gastrectomy to treat obesity at the Quebec Heart and Lung Institute were consecutively recruited in the eastern part of the Quebec Province in Canada. The diagnosis of Type 2 diabetes mellitus [14] was made prior to surgery. Body weight, height, waist circumference, resting SBP [systolic BP (blood pressure)] and DBP (diastolic BP) were measured using standardized procedures [15] . On the day of surgery, fasting blood samples were drawn into EDTAcontaining tubes for DNA extraction and for plasma lipid and glucose concentration measurements [15] . VAT from the greater omentum was sampled during the surgery according to a standardized protocol, as reported previously [16, 17] . Presence of the MetS in the study subjects was diagnosed using the IDF (International Diabetes Federation) criteria [18] . Subjects with the MetS have to be centrally obese (waist circumference 88 cm for women and 102 cm for men; US cut-off values), plus any two of the following CVD risk factors: fasting plasma glucose 5.6 mmol/l or previously diagnosed Type 2 diabetes, HDL (high-density lipoprotein)-cholesterol < 1.29 mmol/l for women and < 1.03 mmol/l for men or specific treatment for this lipid abnormality, TAGs (triacylglycerols) 1.7 mmol/l or specific treatment for this lipid abnormality, SBP 130 mmHg or DBP 85 mmHg or treatment of previously diagnosed hypertension.
The present study was carried out in accordance with the declaration of Helsinki (2000) of the World Medical Association. All patients provided a written informed consent before their inclusion in the study, which received the approval of the Université Laval Ethics Committee.
Confirmation of microarray data using real-time qRT-PCR (quantitative reverse transcription-PCR)
Total RNA extracted from the 14 VAT samples from severely obese men selected previously for the microarray experiment [7] was used for real-time qRT-PCR allowing validation of microarray results. These samples were prepared as described previously [7] . Primers and Taqman probes overlapping the third and the fourth exons of the NM_033035.4 transcript (longer transcript; encoding the functional protein), as well as the first and the second exons of NR_033425.1 transcript (shorter transcript; protein-coding capacity unknown) were obtained from Applied Biosystems (TSLP, Hs00263639_m1). Each sample was analysed in triplicate and calibrated to the GADPH (glyceraldehyde-3-phosphate dehydrogenase) housekeeping gene (endogenous control; GADPH, hs99999905_m1; Applied Biosystems). Relative quantification estimations were performed on an Applied Biosystems 7500 Real-Time PCR System as recommended by the manufacturer, and the C T calculation method [19] was used to evaluate the mean-fold expression difference between men with and without the MetS (see the MetS criteria used in [7] ).
Quantification of TSLP mRNA levels in severely obese men and women
We quantified the TSLP mRNA abundance in VAT from 130 severely obese men and women to confirm the differential TSLP expression as a function of MetS status in a larger sample, as well as to test whether TSLP polymorphisms are predictors of omental TSLP expression. As in the previous microarray experiment [7] , we selected subjects that were non-diabetic, non-smokers and not taking any medication to treat MetS components in order to exclude potential confounding factors on TSLP mRNA abundance. Total RNA was extracted from VAT to generate cDNA [7] and used for real-time qRT-PCR analysis, as described previously [20] . Amplification efficiencies were verified, and quantities of target gene were calculated according to a standard curve prepared from dilutions of pooled samples. Quantities of TSLP mRNA were normalized on quantities of 18S rRNA. The same primers and TaqMan probe as those used for the microarray validation were obtained from Applied Biosystems (TSLP, Hs00263639_m1; r18S, eukaryotic 18S rRNA endogenous control; FAM MGB Probe). Normalized TSLP expression levels were measured for 23 men and 107 women (Table 1 ) and are reported as the fold expression within the subjects.
DNA sequencing, selection of tagging SNPs and genotyping
Genomic DNA was extracted from the buffy coat using the GenElute TM Blood Genomic DNA kit (Sigma). We sequenced 3500 bp upstream of the TSS (translation start site) as well as the coding regions including intronexon splicing boundaries of the TSLP gene in a total of 25 severely obese subjects with (n = 15) and without (n = 10) MetS. This is the minimum number of subjects (n = 25) needed to identify SNPs with an MAF (minor allele frequency) of 5 %, while taking into account a minimum genotyping rate of 80 %. PCR forward and reverse primers were designed using the public [21] , five independent SNPs (LD, r 2 < 0.80) with an MAF 5 % (rs11466749, rs11466750, 1898671, rs2289276 and rs2289277) were genotyped in the study subjects using validated primers and TaqMan probes from Applied Biosystems [7] . Genotypes were determined using a 7500 Real Time PCR System and analysed using the ABI Prism SDS version 1.2.3 software (Applied Biosystems). PCR conditions and primer sequences for TSLP sequencing and genotyping may be obtained from M.-C.V. upon request.
Study design for genotypic association analyses with MetS phenotypes
A two-stage study design was used to verify the presence of associations between TSLP tagging SNPs and MetS phenotypes. This design, developed by Sobell et al. [22] and used previously by our group [20, 23] , consists of sequentially assigning individuals in a first (stage 1) and a second sample (stage 2). The presence of associations between the tagging SNPs and phenotypes was tested in the first sample and only promising associations (P 0.10) were re-tested in the second sample. This strategy has the advantage of decreasing the number of samples needed to achieve statistical significance while accounting for multiple testing issues [24] . It also provides more efficient design to discover new genotypephenotype associations using a joint analysis of the data from both stages [25] , which will then need to be replicated in independent studies. In the present study, subjects were sequentially assigned to the first (n = 638) and the second (n = 645) stage (see Table 3 ). Since a sex-specific effect of TSLP polymorphisms on asthma has been previously reported in humans (sex effect on TSLP expression is still unclear) [26, 27] , the presence of associations was tested separately in men and women.
Statistical analysis
Correlations between microarray and qRT-PCR results were tested using Spearman rank correlation coefficients. Mean TSLP mRNA (log 10 X) levels between individuals with and without the MetS were compared using the GLM (general linear model) and the type III sum of squares without adjustments for confounding factors.
Evaluation of the HW (Hardy-Weinberg) equilibrium between allele frequencies, computation of LD (r 2 ) between TSLP polymorphisms and selection of the tagging SNPs were made with the Tagger program as implemented in Haploview software, version 4.0 [21] . Homozygotes for the minor allele of the tagging SNPs with genotypic frequencies < 5 % were merged with heterozygotes (rs11466749 and rs11466750). A stepwise multiple regression analysis was performed to determine whether TSLP tagging SNPs could predict omental TSLP mRNA levels (log 10 X), among the 130 men and women selected for the qRT-PCR analysis, while including age, sex and waist circumference in the predictive model [SLE (significant level for entry), P = 0.10; and SLS (significant level for elimination), P = 0.05]. Mean TSLP mRNA levels (log 10 X) between genotypes for the independently associated tagging SNP were compared using the GLM and the type III sum of squares without adjustments for confounding factors. Comparisons between genotype groups were performed using the Duncan multiple comparison test when a significant genotype effect was noted. The significant threshold for MetS and genotypic associations with TSLP mRNA levels was set at P < 0.05.
To verify whether subjects' characteristics between stages 1 and 2 were similar, differences in the frequency of smokers, menopausal status (women), Type 2 diabetes and MetS cases between stages were tested using χ 2 analyses separately in men and women. Phenotypes (continuous variables) not normally distributed in all the subjects were transformed. Sex-specific mean phenotypic levels between the two stages were compared using the GLM and the type III sum of squares, where weight (log 10 X), BMI (body mass index) (log 10 X) and waist circumference were adjusted for age and smoking in men, while they were adjusted for age, smoking and menopausal status in women. For plasma glucose ( − 1/X), TAG [ − 1/(1 + X)] and HDL-cholesterol [ − 1/(1 + X)], as well as SBP and DBP, they were adjusted for age, smoking, waist circumference and medication affecting MetS phenotypes in men, while they were adjusted for the same covariables in addition to menopausal status in women.
Sex-specific mean levels for waist circumference, fasting plasma glucose, TAG, HDL-cholesterol, SBP and DBP were compared between genotype groups using the GLM and the type III sum of squares in stage 1, while using the same transformations (for normalization) and adjustments (confounding factors) as described above. Since the effect of the minor allele on MetS phenotypes is unknown, these associations were tested in three different genetic models (as proposed in [28, 29] ): additive (AA compared with AB compared with BB), dominant (AA compared with AB + BB) and recessive (AA + AB compared with BB), while considering A and B as the major and minor allele respectively. Only the dominant model was used for rs11466749 and rs11466750 SNPs, because homozygotes for the minor allele had a frequency < 5 % and were thus combined with heterozygotes. Only the most promising associations (P 0.10) in stage 1 were retested in stage 2 and were considered significant if they reached a P < 0.05 in the second stage.
Statistical analyses were performed using SAS software version 9.2 (SAS Institute).
RESULTS
Validation of lower TSLP expression in VAT of severely obese subjects with the MetS
The TSLP mean fold expression difference between severely obese men with or without the MetS obtained previously in the microarray analysis (− 1.70) was confirmed using relative qRT-PCR (− 1.47). The expression levels ( C T values) measured by these two techniques were significantly correlated (Spearman r = 0.63; P = 0.02).
While comparing TSLP mRNA (log 10 X) levels between subjects with and without the MetS (GLM procedure), the gene expression level was lower in those with the MetS as compared with those without MetS (P = 0.003; no adjustment for confounding factors) ( Figure 1A ). To delineate which MetS phenotypes contribute to this association, further Pearson correlation analyses were performed and they revealed that TSLP expression levels were significantly associated with both TAG (r = − 0.19, P = 0.04) and HDL-cholesterol (r = 0.29, P = 0.001) when adjusted for age, sex and waist circumference (results not shown).
Selection of tagging SNPs and association with TSLP expression
A total of 24 SNPs were identified following sequencing of the promoter region (∼3500 bp) and the four exons including the intron-exon splicing boundaries ( Table 2) . Four rare (MAF = 2 %) SNPs were newly Mean TSLP mRNA levels (log 10 X) between subjects with and without the MetS (MS), as defined using the IDF criteria [18] , were compared using the GLM procedure and the type III sum of squares (no adjustment for confounding factors). (B) Mean TSLP mRNA levels (log 10 X) between genotypes were compared using the GLM and the type III sum of squares (no adjustment for confounding factors). Comparisons among genotype groups were performed using the Duncan multiple comparison test when a significant genotype effect was noted. discovered. Relative to the genomic reference sequence NT_034772.6, they were located before the TSS of the NM_033035.4 transcript (g.18717781A>G, g.18718166G>T and g.18719791A>G) and within the first intron (g.18722280A>G). The other known SNPs were located in non-coding regions such as the promoter region (rs17551370, rs11466728, rs113418941, rs10455025, rs11466733, rs3806932, rs3806933 and rs116647695), the 5 -UTR (untranslated region) (rs2289276), the first (rs1898671 and rs10062929) and the second intron (rs11466741, rs11466742, rs2289277 and rs2289278), as well as within (rs11466749, rs11466750, rs11466752 and rs10073816) and near the end (rs11466754) of the 3 -UTR. Among the 14 common (MAF 5 %) sequence-derived SNPs and taking into account their shared genetic variability (r 2 ), five independent (r 2 < 0.80) SNPs (rs2289276, rs1898671, rs2289277, rs11466749 and rs11466750) were tagged for genotyping (Figure 2) . They allowed the coverage of 92 % of the common and 54 % of the overall sequencederived SNPs. A total of 13 SNPs were indexed in the International HapMap Project (Release 28, August 2010, Build 36) relative to the region sequenced at the TSLP locus and all of them were detected in the study subjects. The five tagging SNPs from the present study allowed the coverage of 11 out of the 12 common TSLP SNPs in HapMap. Only the SNP rs2289278 with a reported MAF of 5 % in HapMap was not covered by this tagging SNP selection. Since its MAF was of less than 5 % in the 25 subjects selected for DNA sequencing, the rs2289278 SNP was not tagged for the subsequent genotyping process.
We observed that among the 130 men and women selected for the qRT-PCR analysis, only the SNP rs2289277 significantly contributed to the TSLP mRNA levels (partial r 2 ×100 = 3.8; P = 0.04), while age, sex and waist circumference were not significant contributors to TSLP gene expression. In fact, homozygotes for the minor allele G (GG) had significantly lower TSLP expression levels as compared with CC and CG individuals (P < 0.05; GLM procedure; no adjustment for confounding factors) ( Figure 1B) .
Characteristics of the study subjects in both stages
As observed in Table 3 , no significant difference was observed regarding smoking habits and menopausal status (women) between stages 1 and 2. The sex-specific anthropometric and clinical mean values between both stages were also similar (see adjustments for confounding factors in the statistical analysis within the Materials and methods section). We observed, however, a significant difference in Type 2 diabetes frequencies between both stages in men (P < 0.05). The study subjects were severely obese with a mean BMI of approximately 52 kg/m 2 . On average, approximately half of them had deteriorated plasma glucose (52-73 %), TAG (51-68 %) and HDLcholesterol levels (60-62 %), and the majority had high BP (69-94 %) and MetS (77-89 %) according to the IDF criteria [18] .
Association between tagging SNPs and MetS phenotypes
Only the results for the dominant genetic model are shown since no significant association was obtained in the additive and recessive models while performing the validation in stage 2. 
Figure 3 Genotypic differences in the mean BP levels for the rs2289277 SNP in all male subjects
Means + − S.E.M are shown. Mean DBP (A) and SBP (B) levels between rs2289277 genotypes (dominant model, CC compared with CG + GG) were compared using the GLM and the type III sum of squares in combined stages 1 and 2 while age, waist circumference, smoking and medication treating hypertension were included in the model.
In male subjects, genotypic association analyses with MetS phenotypes in the first sample (stage 1) revealed potential associations (P 0.10) between rs2289276 and three phenotypes (fasting glucose, P = 0.07; TAG, P = 0.02; HDL-cholesterol, P = 0.08), between rs1898671 and TAG (P = 0.04), between rs2289277 and three phenotypes (waist circumference, P = 0.10; DBP, P = 0.08; SBP, P = 0.07), between rs11466749 and TAG (P = 0.05), as well as rs11466750 and TAG (P = 0.05) (Supplementary Table  S1 at http://www.clinsci.org/cs/123/cs1230099add.htm; see adjustments for confounding factors in the statistical analysis within the Materials and methods section). These associations were tested in the second sample (stage 2) and only the associations between rs2289277 and BP (SBP, P = 0.03; DBP, P = 0.003) remained significant (P < 0.05) (Supplementary Table S1 ). In fact, the mean DBP ( Figure 3A) and SBP ( Figure 3B ) levels were significantly lower in carriers of the minor allele G (CG + GG) compared with CC homozygotes after adjustments for age, waist circumference, smoking and medication treating hypertension (DBP, P = 0.0003; SBP, P = 0.004), while combining men from stages 1 and 2. The rs2289277 SNP explained 3.81 % of the DBP variance and 2.27 % of the SBP variance when including confounding factors in the GLM. We also compared frequencies of male subjects with and without the MetS between genotype groups using logistic regression analyses in stage 1, but no promising association was seen between the tagging SNPs and MetS status (results not shown).
In female subjects, genotypic association analyses with MetS phenotypes in the first sample (stage 1) revealed potential associations between both rs2289276 and rs1898671 with TAG using the relaxed significance level (P 0.10) (Supplementary Table  S2 at http://www.clinsci.org/cs/123/cs1230099add.htm). These associations were re-analysed in the second stage and none of them was significant at P < 0.05. Of note, no association between the tagging SNPs and MetS status was seen in female subjects from stage 1 using logistic regression analyses (results not shown).
DISCUSSION
The TSLP cytokine is known to be constitutively expressed by epithelial cells in the skin, gut and lungs [12] . To the best of our knowledge, expression of TSLP within adipose tissue has never been reported. However, microarray studies implemented in the GEO (Gene Expression Omnibus) database (http://www.ncbi.nlm.nih.gov/geo/; last consultation: 14 September 2011) revealed the presence of TSLP transcripts in human omental adipose tissue of lean and obese subjects (GEO DataSet ID, GDS3688 and GDS3665), as well as of morbidly obese patients (GDS3679). Whether TSLP is expressed by mature adipocytes and/or by stromovascular cells within the VAT remains unclear since we could not identify datasets reporting gene expression data obtained from arrays containing TSLP-specific probes that were performed on distinct fractions of human omental adipose tissue. However, stromovascular cells may be suspected, since mast cells [30] , endothelial cells and VSMC (vascular smooth muscle cells) [31] may express TSLP as observed in other human tissues [12] . Further analyses on the various VAT cell types are needed.
The present study is the first to report differential TSLP mRNA levels in human adipose tissue of patients with and without the MetS. At first sight, the greater omental TSLP gene expression observed among study subjects without MetS suggest a 'protective' effect of TSLP (this hypothesis is somehow challenged later in the Discussion). The 'protective' observation contrasts with the well-known role of TSLP in Th2-mediated inflammation as observed in asthma and atopic dermatitis [9] . However, TSLP may also limit the production of nonprotective Th1 cytokines and inflammation [8] , as seen in Crohn's disease [32, 33] and vitiligo [34] . Interestingly, studies have reported a shift from Th2 to Th1 polarized T-cells in adipose tissue during the development of obesity, which contributed to the progression of adipose tissue inflammation and insulin resistance [11, 35] . These results suggest that higher TSLP expression may be related to lower VAT inflammation and obesity-related metabolic complications.
The present study also revealed that, among the five common tagging SNPs genotyped at the TSLP locus, only rs2289277 could predict VAT mRNA levels. This SNP is localized in the second intron of the longer transcript and within the 5 -UTR of the shorter transcript of TSLP. Functional analysis performed by Harada et al. [36] reported no effect of rs2289277 and other surrounding SNPs on the transcriptional activity of the shorter transcript. However, rs2289277 is in perfect LD with rs3806933 localized in the promoter region of the longer transcript. Two functional studies reported an increase in the transcriptional efficiency of TSLP (longer transcript) in the presence of the rs3806933 minor allele [34, 36] . This SNP was found to create a binding site for the transcription factor AP-1 (activating protein-1) [36] . In the present study, lower TSLP mRNA levels were observed among homozygotes for the minor allele rs2289277. Accordingly, our results are not concordant with those reported previously [34, 36] . This could be partly explained by an independent effect of rs2289277 on TSLP expression in adipose tissue and/or the effects of functional SNPs in partial to complete LD. Although most of the TSLP expression variance remains unexplained, the SNP rs2289277 covered a non-negligible part of this variance (3.8 %) .
Recent studies have reported several associations between common non-coding SNPs at the TSLP locus and immune disorders [26, 27, 34, [37] [38] [39] [40] [41] despite the lack of clear knowledge about their effect on the protein expression and functionality. Since TSLP may be associated with MetS and its phenotypes, further genetic association analyses were conducted in two independent samples of severely obese subjects (sex-stratified). The rs2289277 SNP was significantly associated with BP in men, among whom carriers of the minor G allele (CG + GG) had lower SBP and DBP than homozygotes for the common allele. Beside the possible independent effect of rs2289277, this association may be the result of other SNPs in LD, such as rs3806933 associated previously with lower lung function [39] , asthma [37] and food sensitization [38] . In contrast, the rs3806933 minor allele may be protective against vitiligo (a Th1-dominant immune response disease), which supports a protective role of TSLP in this disease [34] . Since T-cells in atherosclerotic lesions seem to be Th1-polarized and that Th1-releasing cytokines may contribute to hypertension development [42] , it is tempting to suggest a protective role for TSLP in hypertension. However, we observed lower TSLP expression in VAT in the presence of the rs2289277 minor allele along with lower BP in male subjects, which alternatively suggests that lower TSLP gene expression in the whole organism (not specifically in the VAT) may favour lower BP. On the basis of these observations, it is difficult at this point to conclude whether TSLP is associated with a better metabolic profile or not.
In the present study, there was sufficient power to detect differences in TSLP mRNA levels between the MetS groups (85 % at α = 0.05 and calculated effect size of 0.27) and between rs2289277 genotypes (93 % at α = 0.05 and calculated effect size of 0.35, additive model) with 130 subjects (GPower software, version 3.1.3). While comparing MetS-related phenotype means between genotypes using a dominant model, sufficient power was also expected in men and women of stage 1 (at α = 0.10; men: 84 %, n = 189; women: 99 %, n = 449) and of stage 2 (at α = 0.05; men: 77 %, n = 200; women: 99 %, n = 445) when using a medium effect size of 0.25 [43] . However, relatively to the association observed between the SNP rs2289277 and BP in men, the effect size was smaller than what was expected. The calculated effect size was 0.15 for the SBP and 0.20 for the DBP when combining men of both stages, which gave a power of 58 % and 81 % at α = 0.05 respectively. Thus the analyses may be underpowered in the case where TSLP tagging SNPs would have a small effect on the studied phenotypes. Considering this issue, conclusions in the absence of associations between the tagging SNPs and MetS-related phenotypes should not be taken as definitive and more subjects would be needed to detect associations in the case of small effect size. Since the availability of severely obese subjects was limited in this study, combining data from other severely obese cohorts may be an option with which to overcome this issue, but heterogeneity between the different populations would need to be considered. The actual study subjects were recruited in the eastern part of the Quebec province, a region with a relatively homogeneous population in terms of lifestyle, genetic drift and ethnic origins [44] [45] [46] . Thus a major population admixture in the actual study is less probable. Furthermore, subjects of both stages were similar in terms of anthropometric and metabolic characteristics, as well as genotypic frequencies, which would exclude heterogeneity between both stages.
In conclusion, lower TSLP mRNA levels were observed in the VAT of severely obese individuals with the MetS as compared with those without. The TSLP rs2289277 SNP was associated with TSLP gene expression in VAT of men and women and with lower SBP and DBP among severely obese men. This initial study revealed new associations between the TSLP gene and MetS-related phenotypes which will need to be replicated in independent studies. Further replication and functional studies will undoubtedly help to validate the putative functional role of rs2289277 or other SNPs in LD on BP regulation, as well as regarding the implication of the TSLP protein in the development of MetS and its related phenotypes.
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